All companies › DFTX

DFTX · Definium Therapeutics, Inc.

Everything on this page is public record — SEC Form 4 filings and congressional disclosures — alongside any INSIDER SCANNER research case for this company.

Open-market buys0
Open-market sells6
Research cases0
Last filing2026-09-25

Insider flow: Selling only — a count of disclosed transactions, not a rating or a recommendation.

Insider transaction timeline

Every reported transaction, positioned by trade date. Purchases sit above the axis, sales below; circle area is proportional to dollar value. No share-price line is drawn — this feed carries transaction prices only, and a price history inferred from them would imply market data the filings do not contain.

Open-market purchase Open-market sale
2026-09-03 — Barrow Robert · sold 19,023 @ $37.94 2026-09-25 — Roberts Brandi · sold 3,377 @ $36.57 2026-09-25 — Sullivan Mark · sold 14,051 @ $36.57 2026-09-25 — Wiley Matthew T. · sold 3,097 @ $36.57 2026-09-25 — Barrow Robert · sold 31,550 @ $36.57 2026-09-25 — Karlin Daniel · sold 10,853 @ $36.57
2026-09-032026-09-25

Insider participation

One row per insider, one cell per reported transaction, shaded by value. Repeat buying and activity clustered in time are visible at a glance.

Barrow Robert Chief Executive Officer
Roberts Brandi Chief Financial Officer
Sullivan Mark Chief Legal Officer
Wiley Matthew T. Chief Commercial Officer
Karlin Daniel Chief Medical Officer, Director
Included with a free account

The analysis built on top of these filings

The filings above are public record and stay public here. What an account adds for $DFTX is the reading of them — and for this company, that is what the list below says it is, no more.

  • Transaction timelineThe [{'transaction_date': '2026-09-25', 'insider_name': 'Roberts Brandi', 'insider_title': 'Chief Financial Officer', 'transaction_type': 'Open-market sell', 'shares': 3377.0, 'price': 36.57, 'value': 123496.89, 'is_buy': False}, {'transaction_date': '2026-09-25', 'insider_name': 'Sullivan Mark', 'insider_title': 'Chief Legal Officer', 'transaction_type': 'Open-market sell', 'shares': 14051.0, 'price': 36.57, 'value': 513845.07, 'is_buy': False}, {'transaction_date': '2026-09-25', 'insider_name': 'Wiley Matthew T.', 'insider_title': 'Chief Commercial Officer', 'transaction_type': 'Open-market sell', 'shares': 3097.0, 'price': 36.57, 'value': 113257.29, 'is_buy': False}, {'transaction_date': '2026-09-25', 'insider_name': 'Barrow Robert', 'insider_title': 'Chief Executive Officer, Director', 'transaction_type': 'Open-market sell', 'shares': 31550.0, 'price': 36.57, 'value': 1153783.5, 'is_buy': False}, {'transaction_date': '2026-09-25', 'insider_name': 'Karlin Daniel', 'insider_title': 'Chief Medical Officer, Director', 'transaction_type': 'Open-market sell', 'shares': 10853.0, 'price': 36.57, 'value': 396894.21, 'is_buy': False}, {'transaction_date': '2026-09-03', 'insider_name': 'Barrow Robert', 'insider_title': 'Chief Executive Officer', 'transaction_type': 'Open-market sell', 'shares': 19023.0, 'price': 37.94, 'value': 721732.62, 'is_buy': False}] reported transactions plotted over the window rather than listed, so concentration is visible.

Not available for DFTX today: no reported open-market purchases in this window, so there is no insider cost basis to compute; no research case — nothing here has cleared the scoring threshold. Both appear on this page on their own if that changes.

A free account opens all of it.

Not financial advice. This page reports public filings and past research output. It is not a recommendation to buy or sell, and no price target here is a prediction. Trade at your own risk.